Determinants of the Implementation of Human Papillomavirus Vaccination in Zambia: Application of the Consolidated Framework for Implementation Research
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Study Setting
2.3. Sampling
2.4. Data Collection
2.5. Data Management and Analysis
3. Results
3.1. HPV Vaccine Characteristics Domain
3.1.1. HPV Vaccine Trialability (HPV Demonstration Project)
The pilot study was first done in 2013. We were told that we were to give those girls between the age of 9 and 14 but later were changed to those in grade 4. The first pilot we did was very successful as we didn’t have any complaints from mothers or the clients themselves. 009 Midwife
3.1.2. HPV Vaccine Is Offered Free of Charge
So, some of the parents come back to appreciate as they don’t pay for the medicine (HPV vaccine) 021 Teacher
3.1.3. HPV Vaccine Evidence Base
(…) because we are sure we can fight cervical cancer, it is very effective as we are giving the girls to help us fight cervical cancer. 018 Teacher
3.1.4. Myths and Misinformation about the HPV Vaccine
Ah the vaccine at first was very difficult because some parents were saying “Why are you targeting our children from 9 years to 14–15 years? This means you want our children in the coming generation not to come and have, to come and bear children.” 002 Midwife
3.2. Outer Setting—Community
3.2.1. Partnerships and Connection
The main stakeholders we work with are the ward councillors who are the owners of the village because whenever you have to go into the community you have to involve those. Then we also have the health neighbourhood committees in our units who help us with sensitisation issues. Then we also have the teachers in schools because we know that they can sensitise. 012 Public health nurse
3.2.2. Critical Incidents Such as the COVID-19 Pandemic
Because of this COVID-19, most of the parents are not interested in having their children vaccinated thinking we are giving them the COVID-19 vaccine (…) Some say you will become a zombie after some years, some say that they will never have children after vaccination whilst others say you will have blood clots. Those myths are still in the community. I remember before COVID-19, even if not all the children would get parental consent, the number was higher than when we started giving the COVID-19 Vaccine. 004 Midwife
3.2.3. Local Attitudes in the Community
The other challenge is parental consent. We need to educate parents even as we educate their children. So, there is that challenge of them not having the knowledgeon the HPV vaccine. 017 Teacher
Some parents refuse the children from getting vaccinated as they don’t know its benefits so if only they were to be sensitised, and that would make things easier. 007 Teacher
3.3. Inner Setting Domain
3.3.1. Relational Connections among Implementers
We have good teamwork. If we don’t understand something we ask each other together with the new nurses. 004 Midwife
3.3.2. Access to Knowledge and Information about the HPV Vaccine
We had a workshop here where the doctors came, it was a one-day workshop. So, they came with some books and we were told how to go about it (…) they talked about the meaning of HPV; how someone can get it, and the dangers of it if one is not vaccinated, and they talked a lot. They also talked about parents with negative attitudes towards the vaccine and told us to talk to them about the benefits of their children receiving it. 018 Teacher
3.3.3. Materials and Equipment
So, you find that there is only one vehicle that is supposed to take the team to schools and the same vehicle is also supposed to run other errands for the hospital. 009 Midwife
3.3.4. Funding for HPV Vaccination
For us to make sure that this programme is a success, we have to sensitise and for that to work we need the PA system, we need batteries for the megaphone it’s not just a matter of using the PA system, we need also need people to also go door to door. So, the foot soldiers (community volunteers) need to be given something as an incentive because, at the end of the day, they would want to eat because it won’t be effective sensitisation (…). 014 Registered nurse
3.4. Individuals Domain
3.4.1. Opinion Leaders
We have the churches, the church leaders are the ones helping us to sensitise(…) even the marketeers, the chairpersons of these markets because once you go to them, they sensitise them then you find people coming to us. We also use traditional healers. Politicians are also very influential, so we would also go to the MPs [Member of parliament] to help us with sensitisation. So those are the stakeholders we have been using. 009 Midwife
3.4.2. Implementation Team Members
So, we also have champions in communities, we would say in each unit, we would choose a champion for HPV so that one will spearhead even the sensitisation, and registering of pupils, and that makes coordination easier when we collect data from them. We also have champions in schools. Without them, we can barely run the program as a good. 012 Public health nurse
3.4.3. Characteristics Sub-Domain (Capability)
I went for training which I completed I was at UTH [University Teaching Hospital] where I was offered a certificate in cervical cancer screening (…) I have also participated in sensitisation on the transmission of HPV in our catchment area. 002 Midwife
3.5. Implementation Process Domain
3.5.1. Planning for HPV Vaccination
In each school, before starting the programme… we (healthcare workers) would go to a particular school and give the teachers a task to count how many girl children were between the ages of 9 and 14 who were eligible for the vaccine. They would give us (healthcare workers) the number and we would also ask them to give us the date when they expected us to go and vaccinate because we wanted the teachers to also educate the girl child as they are very influential to these girls and their parents. 009 Midwife
3.5.2. Tailoring Strategies to the Local Context
Yes, that education can be given to the parents because what we used to do some time back, we had drama, so we would go out like at the marketplace where those people are found we would go there at the market, and we would have drama teaching people on what exactly would happen if someone had cervical cancer and we would take posters that shows exactly what the cervical cancer is and the normal cervix is so by doing that, people were educated on that one, and that’s what resulted for the parents to bring the children for vaccination. 002 Midwife
3.5.3. Engaging HPV Vaccine Recipients
We use the schools and markets (…) to also cater for those that are not in school as everyone passes through the market. We also use markets during sensitisation. Mothers in the market are mostly there from 6 a.m. to around 20 h (8 p.m.), so they can also get the information and decide to bring their children. 004 Midwife.
3.6. Participants’ Suggestions
Yes, the TV, and radio, and they can also do that by using mobile network carriers like MTN or Airtel to be sending out awareness texts. Then the church also must be involved by making announcements in church which helps some people make better decisions with such issues. Change is a process, until one day they all decide to know the benefits of the vaccine. So, we don’t have to wait for the program to start and then start sensitising, it has to be a continuous thing. 004 Midwife
The teachers also need to be sensitised because as teachers, they can explain better to their pupils, unlike the child only having basic information at the last minute which makes it difficult to explain themselves to the parents. 001 Teacher
4. Discussion
5. Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Yimer, N.B.; Mohammed, M.A.; Solomon, K.; Tadese, M.; Grutzmacher, S.; Meikena, H.K.; Alemnew, B.; Sharew, N.T.; Habtewold, T.D. Cervical cancer screening uptake in Sub-Saharan Africa: A systematic review and meta-analysis. Public Health 2021, 195, 105–111. [Google Scholar] [CrossRef]
- De Vuyst, H.; Alemany, L.; Lacey, C.; Chibwesha, C.J.; Sahasrabuddhe, V.; Banura, C.; Denny, L.; Parham, G.P. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013, 31 (Suppl. 5), F32–F46. [Google Scholar] [CrossRef]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer 2021, 149, 778–789. [Google Scholar] [CrossRef]
- Ministry of Health Zambia. Zambia Population-Based HIV Impact Assessment (ZAMPHIA) 2016: Final Report. Lusaka 2019. Available online: https://phia.icap.columbia.edu/zambia-final-report/ (accessed on 20 September 2022).
- Rohner, E.; Mulongo, M.; Pasipamire, T.; Oberlin, A.M.; Goeieman, B.; Williams, S.; Lubeya, M.K.; Rahangdale, L.; Chibwesha, C.J. Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa(a). Int. J. Gynaecol. Obstet. 2021, 152, 53–59. [Google Scholar] [CrossRef]
- Nyambe, A.; Lubeya, M.K. Cervical cancer and HIV in Zambian women. Lancet Glob. Health 2021, 9, e734–e735. [Google Scholar] [CrossRef]
- Pry, J.M.; Manasyan, A.; Kapambwe, S.; Taghavi, K.; Duran-Frigola, M.; Mwanahamuntu, M.; Sikazwe, I.; Matambo, J.; Mubita, J.; Lishimpi, K.; et al. Cervical cancer screening outcomes in Zambia, 2010–2019: A cohort study. Lancet Glob. Health 2021, 9, e832–e840. [Google Scholar] [CrossRef]
- Menon, S.; Rossi, R.; Zdraveska, N.; Kariisa, M.; Acharya, S.D.; Vanden Broeck, D.; Callens, S. Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: Current evidence and directions for future research. BMJ Open 2017, 7, e015123. [Google Scholar] [CrossRef]
- Stelzle, D.; Tanaka, L.F.; Lee, K.K.; Ibrahim Khalil, A.; Baussano, I.; Shah, A.S.V.; McAllister, D.A.; Gottlieb, S.L.; Klug, S.J.; Winkler, A.S.; et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob. Health 2021, 9, e161–e169. [Google Scholar] [CrossRef]
- Nyambe, A.; Kampen, J.K.; Baboo, S.K.; Van Hal, G. Knowledge, attitudes and practices of cervical cancer prevention among Zambian women and men. BMC Public Health 2019, 19, 508. [Google Scholar] [CrossRef]
- Lubeya, M.K.; Chibwesha, C.J.; Mwanahamuntu, M.; Mukosha, M.; Maposa, I.; Kawonga, M. Correlates of Parental Consent to Human Papillomavirus Vaccine Uptake by Their Adolescent Daughters in ZAMBIA: Application of the Health Belief Model. Vaccines 2023, 11, 912. Available online: https://mdpi-res.com/d_attachment/vaccines/vaccines-11-00912/article_deploy/vaccines-11-00912.pdf?version=1682672042 (accessed on 1 May 2023). [CrossRef]
- Mwamba Mumba, J.; Kasonka, L.; Basil Owiti, O.; Andrew, J.; Ketty Lubeya, M.; Lukama, L.; Kasempa, C.; Msadabwe, S.C.; Kalinda, C. Cervical cancer diagnosis and treatment delays in the developing world: Evidence from a hospital-based study in Zambia. Gynecol. Oncol. Rep. 2021, 37, 100784. [Google Scholar] [CrossRef]
- Kayombo, M. Zambia’s Hurdles in Cervical Cancer Fight. Daily Mail. Available online: http://www.daily-mail.co.zm/zambias-hurdles-in-cervical-cancer-fight/ (accessed on 3 March 2022).
- Amponsah-Dacosta, E.; Kagina, B.M.; Olivier, J. Health systems constraints and facilitators of human papillomavirus immunization programmes in sub-Saharan Africa: A systematic review. Health Policy Plan. 2020, 35, 701–717. [Google Scholar] [CrossRef]
- Oketch, S.Y.; Ochomo, E.O.; Orwa, J.A.; Mayieka, L.M.; Abdullahi, L.H. Communication strategies to improve human papillomavirus (HPV) immunisation uptake among adolescents in sub-Saharan Africa: A systematic review and meta-analysis. BMJ Open 2023, 13, e067164. [Google Scholar] [CrossRef]
- Kutz, J.-M.; Rausche, P.; Gheit, T.; Puradiredja, D.I.; Fusco, D. Barriers and facilitators of HPV vaccination in sub-saharan Africa: A systematic review. BMC Public Health 2023, 23, 974. [Google Scholar] [CrossRef]
- Nabirye, J.; Okwi, L.A.; Nuwematsiko, R.; Kiwanuka, G.; Muneza, F.; Kamya, C.; Babirye, J.N. Health system factors influencing uptake of Human Papilloma Virus (HPV) vaccine among adolescent girls 9-15 years in Mbale District, Uganda. BMC Public Health 2020, 20, 171. [Google Scholar] [CrossRef]
- Soi, C.; Gimbel, S.; Chilundo, B.; Muchanga, V.; Matsinhe, L.; Sherr, K. Human papillomavirus vaccine delivery in Mozambique: Identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR). Implement. Sci. 2018, 13, 151. [Google Scholar] [CrossRef]
- Warner, E.L.; Ding, Q.; Pappas, L.; Bodson, J.; Fowler, B.; Mooney, R.; Kirchhoff, A.C.; Kepka, D. Health Care Providers’ Knowledge of HPV Vaccination, Barriers, and Strategies in a State with Low HPV Vaccine Receipt: Mixed-Methods Study. JMIR Cancer 2017, 3, e12. [Google Scholar] [CrossRef]
- Lubeya, M.K.; Zekire Nyirenda, J.C.; Chanda Kabwe, J.; Mukosha, M. Knowledge, Attitudes and Practices Towards Human Papillomavirus Vaccination among Medical Doctors at a Tertiary Hospital: A Cross Sectional Study. Cancer Control 2022, 29, 10732748221132646. [Google Scholar] [CrossRef]
- Damschroder, L.J.; Aron, D.C.; Keith, R.E.; Kirsh, S.R.; Alexander, J.A.; Lowery, J.C. Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science. Implement. Sci. 2009, 4, 50. [Google Scholar] [CrossRef] [PubMed]
- Kirk, M.A.; Kelley, C.; Yankey, N.; Birken, S.A.; Abadie, B.; Damschroder, L. A systematic review of the use of the Consolidated Framework for Implementation Research. Implement. Sci. 2016, 11, 72. [Google Scholar] [CrossRef] [PubMed]
- Damschroder, L.J.; Reardon, C.M.; Widerquist, M.A.O.; Lowery, J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement. Sci. 2022, 17, 75. [Google Scholar] [CrossRef]
- Saunders, B.; Sim, J.; Kingstone, T.; Baker, S.; Waterfield, J.; Bartlam, B.; Burroughs, H.; Jinks, C. Saturation in qualitative research: Exploring its conceptualization and operationalization. Qual. Quant. 2018, 52, 1893–1907. [Google Scholar] [CrossRef]
- Braun, V.; Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 2006, 3, 77–101. [Google Scholar] [CrossRef]
- Shasha, Y.; Fang, W.; Xi, L.; Meng, J.; Miaomiao, T. Facilitators and barriers to implement the family doctor contracting services in China: Findings from a qualitative study. BMJ Open 2019, 9, e032444. [Google Scholar] [CrossRef]
- Cilenti, D.; Brownson, R.C.; Umble, K.; Erwin, P.C.; Summers, R. Information-seeking behaviors and other factors contributing to successful implementation of evidence-based practices in local health departments. J. Public Health Manag. Pract. 2012, 18, 571–576. [Google Scholar] [CrossRef] [PubMed]
- Green, C.A.; McCarty, D.; Mertens, J.; Lynch, F.L.; Hilde, A.; Firemark, A.; Weisner, C.M.; Pating, D.; Anderson, B.M. A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J. Subst. Abus. Treat. 2014, 46, 390–401. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, B.C.; Harris, I.B.; Beckman, T.J.; Reed, D.A.; Cook, D.A. Standards for Reporting Qualitative Research: A Synthesis of Recommendations. Acad. Med. 2014, 89, 1245–1251. [Google Scholar] [CrossRef]
- Gavi Full Country Evaluations Team. Zambia: Finding from the 2015 GAVI Full Country Evaluation; IHME: Seattle, WA, USA, 2016; Available online: https://www.gavi.org/sites/default/files/document/2015-fce-zambia-briefpdf.pdf (accessed on 25 March 2023).
- Brown, B.; Folayan, M. Barriers to uptake of human papilloma virus vaccine in Nigeria: A population in need. Niger Med. J. 2015, 56, 301. [Google Scholar] [CrossRef]
- Zheng, L.; Wu, J.; Zheng, M. Barriers to and Facilitators of Human Papillomavirus Vaccination among People Aged 9 to 26 Years: A Systematic Review. Sex. Transm. Dis. 2021, 48, e255–e262. [Google Scholar] [CrossRef]
- World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem; World Health Organisation: Geneva, Switzerland, 2020; ISBN 978-92-4-001410-7. Available online: https://www.who.int/publications/i/item/9789240014107 (accessed on 3 March 2022).
- Lubeya, M.K.; Mwanahamuntu, M.; Chibwesha, C.J.; Mukosha, M.; Monde, M.W.; Kawonga, M. Implementation Strategies Used to Increase Human Papillomavirus Vaccination Uptake by Adolescent Girls in Sub-Saharan Africa: A Scoping Review. Vaccines 2023, 11, 1246. Available online: https://mdpi-res.com/d_attachment/vaccines/vaccines-11-01246/article_deploy/vaccines-11-01246.pdf?version=1689505244 (accessed on 16 July 2023). [CrossRef] [PubMed]
- Venturas, C.; Umeh, K. Health professional feedback on HPV vaccination roll-out in a developing country. Vaccine 2017, 35, 1886–1891. [Google Scholar] [CrossRef] [PubMed]
- World Health Organisation, Africa First Lady Launches the HPV Vaccine Project for the Prevention of Cervical Cancer. 15 April 2015. Available online: https://www.afro.who.int/news/first-lady-launches-hpv-vaccine-project-prevention-cervical-cancer (accessed on 5 January 2023).
- Guide to Introducing HPV Vaccine into National Immunization Programmes 2016. Available online: https://apps.who.int/iris/handle/10665/253123 (accessed on 25 August 2022).
- Lubeya, M.K.; Chibwesha, C.J.; Mwanahamuntu, M.; Mukosha, M.; Frank, S.; Kawonga, M. “When you get the HPV vaccine, it will prevent cervical cancer; it will act as a shield”: Adolescent girls’ knowledge and perceptions regarding the human papillomavirus vaccine in Zambia. Front. Health Serv. 2023, 3, 1208458. [Google Scholar] [CrossRef] [PubMed]
- Yohannes, E.; Beyen, M.W.; Bulto, G.A.; Chaka, E.E.; Debelo, B.T.; Erena, M.M.; Tasu, T.L. Knowledge and attitude toward human papillomavirus vaccination and associated factors among adolescent school girls in Ambo town, Ethiopia, 2021: A multicenter cross-sectional study. Health Sci. Rep. 2023, 6, e1305. [Google Scholar] [CrossRef] [PubMed]
- Iova, C.F.; Badau, D.; Daina, M.D.; Șuteu, C.L.; Daina, L.G. Evaluation of the Knowledge and Attitude of Adolescents Regarding the HPV Infection, HPV Vaccination and Cervical Cancer in a Region from the Northwest of Romania. Patient Prefer. Adherence 2023, 17, 2249–2262. [Google Scholar] [CrossRef] [PubMed]
- Batista Ferrer, H.; Trotter, C.L.; Hickman, M.; Audrey, S. Barriers and facilitators to uptake of the school-based HPV vaccination programme in an ethnically diverse group of young women. J. Public Health 2016, 38, 569–577. [Google Scholar] [CrossRef]
- Gilkey, M.B.; Mohan, D.; Janssen, E.M.; McRee, A.L.; Kornides, M.L.; Bridges, J.F.P. Exploring variation in parental worries about HPV vaccination: A latent-class analysis. Hum. Vaccines Immunother. 2019, 15, 1745–1751. [Google Scholar] [CrossRef]
- Gilkey, M.B.; Calo, W.A.; Marciniak, M.W.; Brewer, N.T. Parents who refuse or delay HPV vaccine: Differences in vaccination behavior, beliefs, and clinical communication preferences. Hum. Vaccines Immunother. 2017, 13, 680–686. [Google Scholar] [CrossRef]
- Wong, L.P.; Wong, P.F.; Megat Hashim, M.; Han, L.; Lin, Y.; Hu, Z.; Zhao, Q.; Zimet, G.D. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. Hum. Vaccines Immunother. 2020, 16, 1611–1622. [Google Scholar] [CrossRef]
- Pugliese-Garcia, M.; Heyerdahl, L.W.; Mwamba, C.; Nkwemu, S.; Chilengi, R.; Demolis, R.; Guillermet, E.; Sharma, A. Factors influencing vaccine acceptance and hesitancy in three informal settlements in Lusaka, Zambia. Vaccine 2018, 36, 5617–5624. [Google Scholar] [CrossRef]
- Kucheba, F.; Mweemba, O.; Matenga, T.F.L.; Zulu, J.M. Acceptability of the human papillomavirus vaccine in schools in Lusaka in Zambia: Role of community and formal health system factors. Glob. Public Health 2021, 16, 378–389. [Google Scholar] [CrossRef] [PubMed]
- Mabeya, H.; Menon, S.; Weyers, S.; Naanyu, V.; Mwaliko, E.; Kirop, E.; Orango, O.; Vermandere, H.; Vanden Broeck, D. Uptake of three doses of HPV vaccine by primary school girls in Eldoret, Kenya; a prospective cohort study in a malaria endemic setting. BMC Cancer 2018, 18, 557. [Google Scholar] [CrossRef] [PubMed]
- Kolek, C.O.; Opanga, S.A.; Okalebo, F.; Birichi, A.; Kurdi, A.; Godman, B.; Meyer, J.C. Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya-Findings and Implications. Vaccines 2022, 10, 1185. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.-M.; Riesche, L.; Lee, H.; Shim, K. Parental HPV knowledge and perceptions of HPV vaccines among Korean American parents. Appl. Nurs. Res. 2018, 44, 54–59. [Google Scholar] [CrossRef] [PubMed]
- Simuyemba, M.C.; Chama-Chiliba, C.M.; Chompola, A.; Sinyangwe, A.; Bchir, A.; Asiimwe, G.; Masiye, F.; Chibwesha, C. An Evaluation of the Cost of Human Papilloma Virus (HPV) Vaccine Delivery in Zambia. Res. Sq. 2023. [Google Scholar] [CrossRef]
- Foss, H.S.; Oldervoll, A.; Fretheim, A.; Glenton, C.; Lewin, S. Communication around HPV vaccination for adolescents in low- and middle-income countries: A systematic scoping overview of systematic reviews. Syst. Rev. 2019, 8, 190. [Google Scholar] [CrossRef] [PubMed]
- Dempsey, A.F.; Pyrznawoski, J.; Lockhart, S.; Barnard, J.; Campagna, E.J.; Garrett, K.; Fisher, A.; Dickinson, L.M.; O’Leary, S.T. Effect of a Health Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized Clinical Trial. JAMA Pediatr. 2018, 172, e180016. [Google Scholar] [CrossRef] [PubMed]
- Constable, C.; Ferguson, K.; Nicholson, J.; Quinn, G.P. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: A systematic review. CA Cancer J Clin. 2022, 72, 561–569. [Google Scholar] [CrossRef]
- Dempsey, A.F.; O’Leary, S.T. Human Papillomavirus Vaccination: Narrative Review of Studies on How Providers’ Vaccine Communication Affects Attitudes and Uptake. Acad Pediatr. 2018, 18, S23–S27. [Google Scholar] [CrossRef]
- Corcoran, B.; Clarke, A.; Barrett, T. Rapid response to HPV vaccination crisis in Ireland. Lancet 2018, 391, 2103. [Google Scholar] [CrossRef]
- Mallory, M.L.; Lindesmith, L.C.; Baric, R.S. Vaccination-induced herd immunity: Successes and challenges. J. Allergy Clin. Immunol. 2018, 142, 64–66. [Google Scholar] [CrossRef] [PubMed]
- Brisson, M.; Bénard, É.; Drolet, M.; Bogaards, J.A.; Baussano, I.; Vänskä, S.; Jit, M.; Boily, M.C.; Smith, M.A.; Berkhof, J.; et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: A systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016, 1, e8–e17. [Google Scholar] [CrossRef] [PubMed]
- Keddy, K.H.; Rachmawati, T. Herd immunity or health equity?–extending HPV vaccination. Lancet Reg. Health West. Pac. 2023, 36, 100793. [Google Scholar] [CrossRef] [PubMed]
- Lubeya, M.K.; Mwanahamuntu, M.; Chibwesha, C.; Mukosha, M.; Wamunyima, M.M.; Kawonga, M. Implementation strategies to increase human papillomavirus vaccination uptake for adolescent girls in sub-Saharan Africa: A scoping review protocol. PLoS ONE 2022, 17, e0267617. [Google Scholar] [CrossRef]
Sn | Age | Sex | Profession |
---|---|---|---|
001 | 35 | Female | Teacher |
002 | 50 | Female | Midwife |
003 | 48 | Male | Teacher |
004 | 49 | Female | Midwife |
005 | 54 | Female | Teacher |
006 | 44 | Female | Teacher |
007 | 42 | Female | Teacher |
008 | 39 | Female | General nurse |
009 | 60 | Female | Midwife |
010 | 41 | Female | Public health nurse |
011 | 43 | Female | Teacher |
012 | 36 | Female | Public health nurse |
013 | 25 | Female | General nurse |
014 | 30 | Female | Registered nurse |
015 | 47 | Female | Midwife |
016 | 57 | Female | Teacher |
017 | 54 | Male | Teacher |
018 | 45 | Male | Teacher |
019 | 46 | Female | Teacher |
020 | 28 | Female | Teacher |
021 | 22 | Female | Teacher |
022 | 37 | Female | Public health nurse |
023 | 35 | Female | Midwife |
Sn | Domain | Facilitators | Barriers |
---|---|---|---|
1. | Innovation characteristics |
|
|
2. | Outer setting |
|
|
3. | Inner setting |
|
|
4. | Individual’s domain |
| |
5. | Implementation process domain |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lubeya, M.K.; Chibwesha, C.J.; Mwanahamuntu, M.; Mukosha, M.; Vwalika, B.; Kawonga, M. Determinants of the Implementation of Human Papillomavirus Vaccination in Zambia: Application of the Consolidated Framework for Implementation Research. Vaccines 2024, 12, 32. https://doi.org/10.3390/vaccines12010032
Lubeya MK, Chibwesha CJ, Mwanahamuntu M, Mukosha M, Vwalika B, Kawonga M. Determinants of the Implementation of Human Papillomavirus Vaccination in Zambia: Application of the Consolidated Framework for Implementation Research. Vaccines. 2024; 12(1):32. https://doi.org/10.3390/vaccines12010032
Chicago/Turabian StyleLubeya, Mwansa Ketty, Carla J. Chibwesha, Mulindi Mwanahamuntu, Moses Mukosha, Bellington Vwalika, and Mary Kawonga. 2024. "Determinants of the Implementation of Human Papillomavirus Vaccination in Zambia: Application of the Consolidated Framework for Implementation Research" Vaccines 12, no. 1: 32. https://doi.org/10.3390/vaccines12010032
APA StyleLubeya, M. K., Chibwesha, C. J., Mwanahamuntu, M., Mukosha, M., Vwalika, B., & Kawonga, M. (2024). Determinants of the Implementation of Human Papillomavirus Vaccination in Zambia: Application of the Consolidated Framework for Implementation Research. Vaccines, 12(1), 32. https://doi.org/10.3390/vaccines12010032